

- **Name:** **Se-Hoon Lee**
- **Current Position & Affiliation:** **Professor, Samsung Medical Center**
- **Country:** **Korea**

• **Educational Background:**

Year	<u>Institute</u>	Position
1996	College of Medicine, Seoul National University, Seoul, Korea	M.D.
2008	Graduate School, Seoul National University, Seoul, Korea	Ph.D.
2001	Seoul National University Hospital, Seoul, Korea	Residency
2002	Seoul National University Hospital, Seoul, Korea	Fellowship
2004	Samsung Medical Center, Sungkyunkwan University, Seoul, Korea	Fellowship

• **Professional Experience:**

Year	<u>Institute</u>	Position
2005~2015	Seoul National University Hospital, Seoul, Korea	Assistant and Associate Professor
2009~2010	Dana-Farber Cancer Institute, Boston, MA (Harvard Medical School) & Broad Institute, Cambridge, MA	Visiting Scholar
2015~	Samsung Medical Center, Sungkyunkwan University, Seoul, Korea	Professor

• **Professional Organizations:**

Samsung Medical Center, Sungkyunkwan University, Seoul, Korea

• **Main Scientific Publications:**

1. Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, Lee SH. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. **Ann Oncol**. 2020. doi: 10.1016/j.annonc.2020.04.004. [corresponding author]

2. Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. **Cancer**. 2020 Mar 10. doi: 10.1002/cncr.32809. [Epub ahead of print] PubMed PMID: 32154925. [corresponding author]
3. Kim K, Kim HS, Kim JY, Jung H, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Choi JK. Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. **Nat Commun**. 2020 Feb 19;11(1):951. doi: 10.1038/s41467-020-14562-z. PubMed PMID: 32075964; PubMed Central PMCID: PMC7031381. [corresponding author]
4. Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, Park K, Esteller M, Lee SH, Choi JK. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. **Nat Commun**. 2019 Sep 19;10(1):4278. [corresponding author]
5. Kim HS, Cha H, Kim J, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. **Eur J Cancer**. 2019 Sep 4;120:65-74. [corresponding author]
6. Kim Y, Kim CH, Lee HY, Lee SH, Kim HS, Lee S, Cha H, Hong S, Kim K, Seo SW, Sun JM, Ahn MJ, Ahn JS, Park K. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. **J Thorac Oncol**. 2019 Jun 10. [Epub ahead of print] [first author]
7. Shin SH, Park HY, Im Y, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee HY, Lee SH. Improved Treatment Outcome of Pembrolizumab in Patients with Non-small Cell Lung Cancer and Chronic Obstructive Pulmonary Disease. **Int J Cancer**. 2019 Feb 26. [Epub ahead of print] [corresponding author]
8. Kim Y, Lee B, Shim JH, Lee SH, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K. Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer. **J Thorac Oncol**. 2018 Oct 31. [corresponding author]